A Randomized, Double-Blind Phase II Study of Sipuleucel-T (Provenge) Followed by Indoximod or Placebo in the Treatment of Patients With Asymptomatic or Minimally Symptomatic Metastatic Castration Resistant Prostate Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 09 May 2018
At a glance
- Drugs Indoximod (Primary) ; Sipuleucel-T (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 01 May 2018 Planned End Date changed from 1 Nov 2019 to 1 Nov 2020.
- 01 May 2018 Planned primary completion date changed from 1 Apr 2018 to 1 Apr 2019.
- 23 Oct 2017 Planned End Date changed from 1 Nov 2017 to 1 Nov 2019.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History